Sign In
Buy PDS
$95.01
+1.95 (+2.10%)
At Close: Jun 03, 2026
Analysts Estimate Precision Drilling (PDS) to Report a Decline in Earnings: What to Look Out for
11:07am, Tuesday, 22'nd Jul 2025
Precision Drilling (PDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PRINCETON, N.J., July 10, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how
Explore the booming Global Deep Hole Drilling Machine Market, poised to surge from USD 1.13 Billion in 2025 to USD 1.77 Billion by 2034, a 6.6% CAGR growth. Essential for precision sectors like aerosp
Precision Drilling Corporation 2025 Second Quarter Results Conference Call and Webcast
04:00pm, Wednesday, 02'nd Jul 2025
CALGARY, Alberta, July 02, 2025 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision) intends to release its 2025 second quarter results after the market closes on Tuesday, July 29, 2025, and
Oil & Gas Drilling Is Struggling - But These 3 Names Stand Out
09:25am, Wednesday, 18'th Jun 2025
Scale, innovation and disciplined execution help PTEN, RIG, and PDS stand out in a slumping drilling industry.
PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC
08:00am, Monday, 09'th Jun 2025
Event to Discuss the Changing Landscape of HNSCC in context with the Merck KN-689 study and the Rapidly Increasing Incidences of HPV16-positive HNSCC in the United States and Europe
PDS Biotech announced the publication of three Versamune® HPV abstracts that were presented during the Head and Neck Cancer Poster Session at ASCO 2025.
Precision Drilling: Oilfield Activity In Canada Appears Resilient, So Far
01:00pm, Tuesday, 27'th May 2025
Oil drilling activity in the U.S. will be cut back due to low prices. However, drilling in Canada is robust due to structural factors, at least for now. Precision Drilling gets 2/3 of its revenue from
Phase 2: Versamune ® HPV with pembrolizumab as 1L treatment of r/m HPV16-positive HNSCC
PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase
08:00am, Tuesday, 20'th May 2025
PRINCETON, N.J., May 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how
Precision Drilling Corporation Announces Voting Results from the 2025 Annual and Special Meeting of Shareholders
05:00pm, Thursday, 15'th May 2025
CALGARY, Alberta, May 15, 2025 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision or the Company) is pleased to announce the results of the election of board members at its 2025 Annual and
EMV Capital portfolio company PDS Biotech advances cancer trial
02:53am, Thursday, 15'th May 2025
PDS Biotechnology Corporation (NASDAQ:PDSB), a US cancer immunotherapy firm backed by EMV Capital (AIM:EMVC), has begun site activations for its phase III trial of Versamune HPV in patients with head
PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update
07:30am, Wednesday, 14'th May 2025
VERSATILE-003 Phase 3 Site Initiations Underway Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting Conference call and webcast today at 8:00
PDS Health Expands CyberArk Deployment to Automate Certificate Lifecycle Management at Scale
07:30am, Tuesday, 13'th May 2025
NEWTON, Mass. & PETACH TIKVA, Israel--(BUSINESS WIRE)--CyberArk (NASDAQ: CYBR), the global leader in identity security, today announced that PDS Health, a leading integrated healthcare support organiz
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 09'th May 2025
PRINCETON, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how
